Business, energy, technology, markets and global industry news from Business News Today

vosoritide

PharmaDeviceNews vosoritide
Pharma & Biotech

Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?

Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More